L-Arginine FOR SCA6: PHASE2 clinical trial in Japan

Key Points

• L-arginine treatment shows promise in improving neurological function in SCA6 patients, indicating meaningful outcomes.
• The study reports significant improvements in specific biomarkers related to neurological health among participants.
• Phase 2 clinical trial assesses the efficacy of l-arginine in treating a rare genetic neurological disorder called SCA6.
• Findings suggest that l-arginine could become a valuable treatment option, though further studies are warranted.